Docteur Mathilde NICOLAS

Livres & ouvrages

• 📕

  Encadrement des influenceurs en matière de promotion des médicaments en France

  20230

• 📕

  L'association pentoxifylline-tocophérol dans la prise en charge de l'ostéochimionécrose associée aux antirésorbants osseux

  état des connaissances et proposition d'un protocole de recherche clinique

  20220

• 📕

  État des lieux de l'utilisation de l'amitriptyline, dans la prise en charge des douleurs neuropathiques, par les médecins de soins palliatifs en France

  2016 · 320 p.

• 📕

  Caractéristiques des patients évalués à l'hôpital de jour fragilité et bilan à 3 mois

  2015 · 94 p.

Source : Google Books — filtre catégories médicales/santé/sciences.

Lieu de consultation

• GHU APHP CUP SITE COCHIN PORT ROYAL

  27 Rue DU FAUBOURG SAINT JACQUES, 75679 Paris 14e Arrondissement

  ☎ 0158414141Hospitalier🏥 Voir cet établissement

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Vidéos & interventions (3)

Source YouTube · recherche par nom (homonymes possibles).

• 4:32

  Réussis ta PACES avec le Tutorat Santé Rouen

  Tutorat Santé Rouen · 5 k vues

• 1h39

  Limites et complications des implants zygomatiques - Philippe JABY

  Société de Chirurgie Orale SFCO · 600 vues

• 1h37

  Limites et complications des implants zygomatiques - Philippe JABY

  Eugenol · 677 vues

Top publications · les plus citées

• 1

  Long-term follow-up of multilayer amniotic membrane transplantation (MLAMT) for non-traumatic corneal perforations or deep ulcers with descemetocele

  Klinische Monatsblatter fur Augenheilkunde · 2013

  📚 23 citations🎯 RCR 1.22
• 2

  Biomarkers in the era of targeted therapy in giant cell arteritis and polymyalgia rheumatica: is it possible to replace acute-phase reactants?

  Frontiers in immunology · 2023

  📚 16 citations🎯 RCR 2.51Top 20% NIH🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  Research into giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) has become more important in the last few decades. Physicians are facing several challenges in managing the diagnosis, treatment, and relapses of GCA and PMR patients. The search for biomarkers could provide elements to guide a physician’s decision. In this review, we aim to summarize the scientific publications about biomarkers in GCA and PMR in the past decade. The first point raised by this review is the number of clinical situations in which biomarkers could be useful: differential diagnosis of either GCA or PMR, diagnosis of underlying vasculitis in PMR, prediction of relapse or complications, disease activity monitoring, choice, and modification of treatments. The second point raised by this review is the large number of biomarkers studied, from common markers like C-reactive protein, erythrocyte sedimentation rate, or elements of blood count to inflammatory cytokines, growth factors, or immune cell subpopulations. Finally, this review underlines the heterogeneity between the studies and proposes points to consider in studies evaluating biomarkers in general and particularly in the case of GCA and PMR.

• 3

  Invasive fungal diseases in patients with autoimmune diseases: a case series from the French RESSIF network

  RMD open · 2023

  📚 12 citations🎯 RCR 1.82🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  Objectives We aimed to describe patients with autoimmune diseases (AID) developing invasive fungal disease (IFD) and identify factors associated with short-term mortality. Methods We analysed cases of IFD associated with AID from the surveillance network of invasive fungal diseases (Réseau de surveillance des infections fongiques invasives, RESSIF) registry of the French national reference centre for invasive mycoses. We studied association of AID-specific treatments with 30-day mortality. We analysed total lymphocyte and CD4-T cell counts in patients with Pneumocystis jirovecii pneumonia (PCP). Results From 2012 to 2018, 549 individuals with IFD and AID were included, mainly with PCP (n=227, 41.3%), fungemia (n=167, 30.4%) and invasive aspergillosis (n=84, 15.5%). Rheumatoid arthritis (RA) and anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV) were the most frequent AID in PCP (n=55 and 25, respectively) and invasive aspergillosis (n=15 and 10, respectively), inflammatory bowel diseases (IBDs) were predominant in fungemia (n=36). At IFD diagnosis, 365 (66.5%) patients received glucocorticoids (GCs), 285 (51.9%) immunosuppressants, 42 (7.7%) tumor necrosis factor (TNF)-α blockers, 75 (13.7%) other biologics. Mortality at 30 days was 28.1% (143/508). Fungemia and high-dose GCs were independently associated with higher 30-day mortality. In PCP patients, lymphopenia <1500/mm3 was frequent (132/179, 73.7%) even if CD4+T cell count exceeded 200/mm3 in 56/78 patients (71.8%) (median 472.5/mm3, IQR 160–858). Conclusion IFD associated with AID occurs primarily in RA, AAV and IBD, especially when treated with GCs and immunosuppressants. Mortality is high, especially for patients on high-dose GCs. Lymphopenia may help identify risk of PCP, but normal CD4+T cell count does not rule out the risk. Further studies are needed to assess the individual risk factors for IFD.

Publications scientifiques (9) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche